Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
Total raised: $137M
Investors 5
| Date | Name | Website |
| - | adMare Bio... | admarebio.... |
| - | T1D Fund | t1dfund.or... |
| - | Forbion | forbion.co... |
| - | Genesys Ca... | genesyscap... |
| - | Anges Québ... | angesquebe... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.10.2022 | Series C | $95M | - |
| 08.09.2020 | Series B | $35M | Forbion |
| 25.07.2018 | Series A | $7M | - |
Mentions in press and media 12
| Date | Title | Description | Source |
| 17.11.2022 | Forbion Portfolio Company Inversago named in Labiotech list ... | The hottest private biotech companies in Canada BY JONATHAN SMITH NOVEMBER 17, 2022 Canada is wel... | forbion.co... |
| 17.10.2022 | Inversago Pharma Raises $95 million CAD in Series C Financin... | MONTREAL (CANADA) – October 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech... | forbion.co... |
| 17.10.2022 | Inversago Pharma Raises CAD$95M in Series C Financing | Inversago Pharma, a Montreal, Canada-based clinical stage biotech company, raised CA$95M in Series C... | finsmes.co... |
| 17.01.2022 | Inversago Pharma, an adMare Portfolio Company, Completes Pha... | MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, a... | admarebio.... |
| 08.09.2020 | Inversago Pharma Closes US$35M Series B Financing Round and ... | Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today ann... | marketscre... |
| 08.09.2020 | adMare is pleased to increase our investment in Inversago Ph... | Inversago Pharma closes US$35M Series B financing round and expands Board of Directors Vancouver an... | admarebio.... |
| 08.09.2020 | Forbion leads US$35M Series B financing round for Inversago ... | • Funds to pursue development of INV-101 and other promising peripheral CB1 blockers to clinical pro... | forbion.co... |
| 08.09.2020 | Inversago Pharma Closes US$35M Series B Financing Round and ... | Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today ann... | marketscre... |
| 08.09.2020 | Inversago Pharma Closes US$35M Series B Financing | Inversago Pharma Inc., a Montreal, Canada-based peripheral CB1 blockade company, secured a US$35m (€... | finsmes.co... |
| 25.07.2018 | Inversago Pharma Receives $7M in Series A Financing | Inversago Pharma, Inc., a Montreal, Canada-based preclinical-stage biotech company, secured a $7m Se... | finsmes.co... |
Show more